P. Dormitzer

New England Journal of Medicine · 2011–2021

A researcher in the Science corpus: 12 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Whom P. Dormitzer trusts

Their strongest outbound trust, strongest first, inferred from their citations.

1. A. L. Spek (in Materials Chemistry)

Papers from P. Dormitzer's perspective

Ordered by how strongly the researchers P. Dormitzer trusts endorse each paper. Same corpus, a different order for every researcher.

1. Structure validation in chemical crystallography
2. Improved methods for building protein models in electron density maps and the location of errors in these models.
3. Refinement of macromolecular structures by the maximum-likelihood method.
4. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases (Mycopathologia)
5. Correlates of immunity to respiratory syncytial virus (RSV) associated-hospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies.
6. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis (The Lancet)
7. Rational design of cationic lipids for siRNA delivery (Nature Biotechnology)
8. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents (New England Journal of Medicine)
9. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers
10. DNA vaccines: ready for prime time? (Nature reviews genetics)

Their papers

• Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine (2020) — 11,263 citations
• Nonviral delivery of self-amplifying RNA vaccines (2012) — 626 citations
• Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report (2020) — 127 citations
• Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents (2021) — 724 citations
• BNT162b vaccines protect rhesus macaques from SARS-CoV-2 (2021) — 629 citations
• Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months (2021) — 1,225 citations
• BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) — 690 citations
• COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (2020) — 1,578 citations
• Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates (2020) — 2,193 citations
• Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (2020) — 1,348 citations
• Concurrent human antibody andTH1 type T-cell responses elicited by a COVID-19 RNA vaccine (2020) — 87 citations
• Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers (2011) — 274 citations